
    
      A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate
      the effects of rosiglitazone (extended release tablets) as adjunctive therapy to
      acetylcholinesterase inhibitors on cognition and overall clinical response in APOE
      e4-stratified subjects with mild to moderate Alzheimer's disease (REFLECT-3)
    
  